Please login to the form below

Not currently logged in
Email:
Password:

EMA drug communication reviewed

The European Medicines Agency's (EMA) communication strategy concerning the benefits and risks of medicines has been put under the spotlight by an independent report

The European Medicines Agency's (EMA) communication strategy concerning the benefits and risks of medicines has been put under the spotlight by an independent report.

The report represents the outcome of a year-long project carried out by Dr Frederic Bouder, from Maatstricht University, on the invitation of the agency.

Dr Bouder carried out a detailed analysis of the expectations and attitudes of the agency's stakeholders towards its communication on medicines.

He recommended that the agency set up a risk communication advisory board, form a strategic view on transparency, involve patients in communication activities on a routine basis, and review the format and timing of its communication vehicles.

The EMA has started implementing some of Dr Bouder's suggestions. It is also considering his recommendations during the implementation of the new pharmacovigilance legislation.

The EMA has the report available to download (PDF).

1st June 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

Where next in Alzheimer’s disease R&D?
How past failures and emerging biology are reshaping drug development...
Brain scan
Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...

Infographics